Focus: Prellis Biologics is a Berkeley-based biotechnology company specializing in 3D printed vasculature technology and antibody discovery platforms targeting oncology and inflammation. The company operates at the Series C+ stage, indicating mid-stage development with focused therapeutic ambitions.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
No open roles listed right now. Follow Prellis Biologics to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
No open positions listed yet. Check their careers page directly.
Help build intelligence for Prellis Biologics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Prellis Biologics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Recent peer-reviewed publications with author affiliations at this company
Bone Tissue Engineering: Recent Advances and Translation to Clinical Application.
Dysfunctional CD11c(-)CD21(-) extrafollicular memory B cells are enriched in the periphery and tumors of patients with cancer.
Predicting monoclonal antibody binding sequences from a sparse sampling of all possible sequences.
A humanized mouse that mounts mature class-switched, hypermutated and neutralizing antibody responses.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo